TTP Labtech acquires fluorescence lifetime technology
TTP Labtech has consolidated its position in the field of fluorescence lifetime (FLT) technology, having recently purchased assets from UK-based FLT company AssayMetrics.
The acquisition enhances TTP Labtech’s ameon system equipped with real-time decay curve analysis (RT-DCA), licensed from Fluorescence Innovations in the US. The product’s FLT reader technology provides a combination of speed, precision and data quality that can be readily exploited in high-throughput screen (HTS) workflows.
“The development of the ameon reader introduces an exciting new dimension to FLT technology, giving researchers a step-change in sample throughput and data quality,” said Dr Greg Gillispie, president of Fluorescence Innovations.
“Reception to ameon has been very positive,” added Dr Wayne Bowen, chief scientific officer of TTP Labtech, “with early feedback from beta-partners reporting superior tolerance to compound interference compared to established methodologies. Increasing access to relevant instrumentation is revealing the true potential of FLT for cost-critical assays to the screening community.”
Significant improvements in assay reagents and the availability of HTS-compatible readers are said to have propelled FLT technology to the forefront of cost-effective screening technologies.
Australia to begin treaty negotiations on association to Horizon Europe
To give Australian organisations access to the world's largest pooled research fund in 2027,...
Vaxxas partners with AI company Profenso to support quality assurance
A strategic partnership between Vaxxas and Profenso, an Australian AI company specialising in...
SA Police seize 'clandestine laboratory' drug-making equipment
Following a search at Woodville North last week, Western District Police have made one of the...
